{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T11:50:11Z","timestamp":1773402611724,"version":"3.50.1"},"reference-count":3,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2009]]},"DOI":"10.1007\/s10156-009-0683-y","type":"journal-article","created":{"date-parts":[[2009,6,24]],"date-time":"2009-06-24T08:04:27Z","timestamp":1245830667000},"page":"174-179","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Evaluation of the risk factors for febrile neutropenia associated with hematological malignancy"],"prefix":"10.1016","volume":"15","author":[{"given":"Yasunori","family":"Nakagawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenshi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Masaoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1007\/s10156-009-0683-Y_bib0005","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/infdis\/161.3.381","article-title":"From the Infectious Diseases Society of America. Guidelines for the use of antimicrobial agents in neutropenic patients with cancer","volume":"161","author":"Hughes","year":"1990","journal-title":"J Infect Dis"},{"key":"10.1007\/s10156-009-0683-Y_bib0010","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1200\/JCO.2000.18.16.3038","article-title":"The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients","volume":"18","author":"Klastersky","year":"2002","journal-title":"J Clin Oncol"},{"issue":"Suppl1","key":"10.1007\/s10156-009-0683-Y_bib0015","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1086\/383054","article-title":"Evidence-based recommendations for antimicrobial use in febrile neutropenia in Japan: executive summary","volume":"39","author":"Masaoka","year":"2004","journal-title":"Clin Infect Dis"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X09706907?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X09706907?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s10156-009-0683-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T18:46:20Z","timestamp":1761158780000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X09706907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009]]},"references-count":3,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009]]}},"alternative-id":["S1341321X09706907"],"URL":"https:\/\/doi.org\/10.1007\/s10156-009-0683-y","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2009]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of the risk factors for febrile neutropenia associated with hematological malignancy","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s10156-009-0683-Y","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Japanese Society of Chemotherapy and the Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}